Nima Sharifi

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. pmc The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
    Nima Sharifi
    Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Investig Med 60:504-7. 2012
  2. doi request reprint Commentary: Antioxidants for cancer: new tricks for an old dog?
    Nima Sharifi
    Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Oncologist 14:213-5. 2009
  3. ncbi request reprint Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function
    Nima Sharifi
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8852, USA
    Anticancer Agents Med Chem 9:1046-51. 2009
  4. pmc Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer
    Nima Sharifi
    Cancer Stem Cell Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA
    Clin Cancer Res 14:6073-80. 2008
  5. pmc The genetics of castration-resistant prostate cancer: what can the germline tell us?
    Nima Sharifi
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Clin Cancer Res 14:4691-3. 2008
  6. pmc A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer
    Nima Sharifi
    Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
    BJU Int 102:617-21. 2008
  7. pmc An update on androgen deprivation therapy for prostate cancer
    Nima Sharifi
    Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Endocr Relat Cancer 17:R305-15. 2010
  8. pmc Survivin is not induced by novel taxanes
    Nima Sharifi
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390 8852, USA
    Mol Pharm 7:2216-23. 2010
  9. doi request reprint New agents and strategies for the hormonal treatment of castration-resistant prostate cancer
    Nima Sharifi
    Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Expert Opin Investig Drugs 19:837-46. 2010
  10. doi request reprint "Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer
    Nima Sharifi
    Divisions of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
    J Investig Med 58:938-44. 2010

Detail Information

Publications32

  1. pmc The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
    Nima Sharifi
    Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Investig Med 60:504-7. 2012
    ..Further progress in the hormonal treatment of CRPC is dependent on an understanding of the mechanisms that underlie CRPC and resistance to abiraterone acetate...
  2. doi request reprint Commentary: Antioxidants for cancer: new tricks for an old dog?
    Nima Sharifi
    Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Oncologist 14:213-5. 2009
    ..A re-examination of the current evidence and further study is clearly warranted...
  3. ncbi request reprint Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function
    Nima Sharifi
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 8852, USA
    Anticancer Agents Med Chem 9:1046-51. 2009
    ..These agents and the promise of the development of others provide hope that more effective hormonal therapies may soon be offered to patients, which will improve clinical outcomes...
  4. pmc Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer
    Nima Sharifi
    Cancer Stem Cell Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA
    Clin Cancer Res 14:6073-80. 2008
    ..Expression of manganese superoxide dismutase (SOD2), which regulates cellular ROS, is markedly down-regulated in CRPC when compared with hormone-responsive tumors...
  5. pmc The genetics of castration-resistant prostate cancer: what can the germline tell us?
    Nima Sharifi
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Clin Cancer Res 14:4691-3. 2008
    ....
  6. pmc A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer
    Nima Sharifi
    Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
    BJU Int 102:617-21. 2008
    ....
  7. pmc An update on androgen deprivation therapy for prostate cancer
    Nima Sharifi
    Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Endocr Relat Cancer 17:R305-15. 2010
    ..Bone loss and increased risk of fracture may be effectively treated with pharmacologic interventions. Benefits of ADT must be balanced with a consideration of the risks...
  8. pmc Survivin is not induced by novel taxanes
    Nima Sharifi
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390 8852, USA
    Mol Pharm 7:2216-23. 2010
    ..This work suggests that taxanes that effectively bind tubulin need not invariably induce survivin as a mechanism of drug resistance...
  9. doi request reprint New agents and strategies for the hormonal treatment of castration-resistant prostate cancer
    Nima Sharifi
    Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Expert Opin Investig Drugs 19:837-46. 2010
    ..Depletion of gonadal testosterone in circulation is typically initially effective, although responses are transient and metastatic disease progresses as castration-resistant prostate cancer (CRPC)...
  10. doi request reprint "Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer
    Nima Sharifi
    Divisions of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
    J Investig Med 58:938-44. 2010
    ....
  11. doi request reprint Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer
    Rui Li
    Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Clin Cancer Res 18:3571-9. 2012
    ....
  12. pmc Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer
    Akinobu Hamada
    Molecular Pharmacology Section, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Clin Cancer Res 14:3312-8. 2008
    ....
  13. doi request reprint 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer
    Kristen Evaul
    Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    Endocrinology 151:3514-20. 2010
    ..These findings demonstrate that DHEA and A5diol must be metabolized by 3betaHSD to activate AR in these models of CRPC. Furthermore, this work suggests that 3betaHSD may be exploited as a pharmacologic target in the treatment of CRPC...
  14. pmc Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
    Kai Hsiung Chang
    Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Proc Natl Acad Sci U S A 108:13728-33. 2011
    ..These findings reframe the fundamental metabolic pathway that drives CRPC progression, and shed light on the development of new therapeutic strategies...
  15. ncbi request reprint Androgen receptor expression in prostate cancer stem cells: is there a conundrum?
    Nima Sharifi
    Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Cancer Chemother Pharmacol 62:921-3. 2008
    ..Our findings suggest that at least a subset of prostate cancers express AR in the putative stem cell population...
  16. doi request reprint More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer
    Seun Ajiboye
    Molecular Pharmacology Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    BJU Int 105:913-6. 2010
    ....
  17. ncbi request reprint Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy
    Nima Sharifi
    Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, USA
    Cancer Biol Ther 5:901-6. 2006
    ..We propose possible explanations that may resolve this conundrum and discuss implications for hormonal therapy...
  18. ncbi request reprint A retrospective study of the time to clinical endpoints for advanced prostate cancer
    Nima Sharifi
    Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    BJU Int 96:985-9. 2005
    ....
  19. ncbi request reprint TGFBR3 loss and consequences in prostate cancer
    Nima Sharifi
    Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA
    Prostate 67:301-11. 2007
    ..Resistance to transforming growth factor-beta (TGF-beta) is important in tumorigenesis. TGF-beta resistance mechanisms in prostate cancer are not well understood...
  20. ncbi request reprint Androgen receptor modulation: lessons learned from beyond the prostate
    Nima Sharifi
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 6:1358-9. 2007
    ..Here, we examine recent findings from the description of a compound that degrades AR and induces dissociation of AR from an AR coactivator. The biochemistry of this compound may have implications for prostate cancer...
  21. ncbi request reprint Androgen deprivation therapy for prostate cancer
    Nima Sharifi
    Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD 20892, USA
    JAMA 294:238-44. 2005
    ..Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease...
  22. ncbi request reprint Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?
    Nima Sharifi
    Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Center for Cancer Research, Frederick, Maryland 21702, USA
    J Mol Endocrinol 39:329-32. 2007
    ..Two recent papers show that TGF-beta receptor III is the most common TGF-beta pathway component downregulated in prostate cancer. Here, we discuss the implications of these findings and what it may mean about the biology of this disease...
  23. ncbi request reprint Secondary hormonal therapy for prostate cancer: what lies on the horizon?
    Nima Sharifi
    National Cancer Institute, Medical Oncology Branch, Bethesda, Maryland 20892, USA
    BJU Int 101:271-4. 2008
    ..We discuss novel secondary hormonal agents that are under development, which work by either inhibiting androgen synthesis or directly targeting the androgen receptor...
  24. ncbi request reprint A bifunctional colchicinoid that binds to the androgen receptor
    Nima Sharifi
    Room 21 81, Cancer Stem Cell Section, Laboratory of Cancer Prevention, National Cancer Institute at Frederick, Building 560, Frederick, MD 21702, USA
    Mol Cancer Ther 6:2328-36. 2007
    ..Finally, we found that this compound has greater toxicity against androgen-independent prostate cancer cells than the combination of colchicine and nilutamide. Together, these data point to several ways of inhibiting AR function in CRPC...
  25. ncbi request reprint Androgen receptor as a therapeutic target for androgen independent prostate cancer
    Nima Sharifi
    Cytokine Molecular Mechanisms Section, Laboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
    Am J Ther 13:166-70. 2006
    ....
  26. ncbi request reprint Inhibition of 3β-hydroxysteroid dehydrogenase by abiraterone as a rationale for dose escalation in castration-resistant prostate cancer
    Nima Sharifi
    University of Texas Southwestern Medical Center, Dallas, TX University of Michigan, Ann Arbor, MI
    J Clin Oncol 30:209. 2012
    ....
  27. doi request reprint Prostate cancer-from steroid transformations to clinical translation
    Kai Hsiung Chang
    Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Nat Rev Urol 9:721-4. 2012
    ..The specific roles of candidate enzyme targets in the development of resistance to these agents must be defined if we are to identify novel targets for improved pharmacologic therapies...
  28. doi request reprint Steroid biosynthesis and prostate cancer
    Nima Sharifi
    Division of Hematology Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA
    Steroids 77:719-26. 2012
    ....
  29. pmc SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer
    Rusha Thomas
    Department of Internal Medicine, Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Mol Cancer Ther 11:87-97. 2012
    ..Collectively, this study has shown for the first time that SOD mimetics, by virtue of their ability to suppress AR function, may be beneficial in treating the currently incurable CRPC, in which SOD2 expression is highly suppressed...
  30. ncbi request reprint Screening for prostate cancer: current status and future prospects
    Nima Sharifi
    Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Am J Med 120:743-5. 2007
  31. pmc A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer
    Kai Hsiung Chang
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Cell 154:1074-84. 2013
    ..We suggest that 3βHSD1 is a valid target for the treatment of CRPC. ..
  32. ncbi request reprint Perturbations in hypoxia detection: a shared link between hereditary and sporadic tumor formation?
    Nima Sharifi
    Cytokine Molecular Mechanisms Section, Laboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute at Frederick, Bldg 560, Room 21 81, Frederick, MD 21702, USA
    Med Hypotheses 66:732-5. 2006
    ..We survey evidence suggesting that the mechanism of some recognized risk factors of kidney cancer, such as smoking and obesity, may be due in part to tissue hypoxia, reflecting physiologic detection of hypoxia gone awry...